Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Inclusion Criteria: * willing to comply with investigator's and protocol's instructions * patients signature on the informed consent document * primary open-angle glaucoma, pigment dispersion or exfoliation glaucoma, or ocular hypertension in at least one eye * at screening intraocular pressure must be considered to be safe, in both eyes * in non-qualifying eyes the intraocular pressure should be able to be controlled safely on no pharmacologic therapy or on study medicine alone * currently treated with one glaucoma medication, untreated intraocular pressure of less than or equal to 28 mm Hg at visit 2 in both eyes Exclusion Criteria: * any abnormality preventing reliable applanation tonometry in either eye * any opacity or subject uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber in either eye * any concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye * any history of allergic hypersensitivity or poor tolerance to any components of the preparations used in this trial * females of childbearing potential not using reliable means of birth control * pregnant or lactating females * any clinically significant, serious, or severe medical or psychiatric condition * participation (or current participation) in any investigational drug or device trial within 30 days prior to Visit 1 * severe prior visual acuity or field loss from any cause * inability to understand the trial procedures, and thus inability to give informed consent * progressive retinal or optic nerve disease apart from glaucoma * serious systemic or ocular disease * intraocular laser surgery within the past three months or corneal or intraocular conventional surgery within the past 6 months * concurrent use of systemic corticosteroids, by IV, oral, dermal or topical ophthalmic route. * subjects requiring tear replacement drops or allergy medications with sympathomimetics 24 hours prior to a scheduled study visit * contraindication to beta-blocker usage including: reactive airway disease, uncontrolled heart failure, or second as well as third degree cardiac block, myasthenia gravis * any subject the investigator believes will be at risk for glaucomatous progression by their participation in this trial